What is the current valuation of the car t-cell-therapy market in Germany as of 2024?

The market valuation was $692.85 Million in 2024. Read More

What is the projected market valuation for car t-cell-therapy in Germany by 2035?

The projected valuation for 2035 is $3374.8 Million. Read More

What is the expected CAGR for the car t-cell-therapy market in Germany during the forecast period 2025 - 2035?

The expected CAGR during this period is 15.48%. Read More

Which therapeutic areas are leading in the car t-cell-therapy market in Germany?

Oncology leads with a valuation range of $300.0 Million to $1500.0 Million. Read More

What are the key cell sources utilized in the car t-cell-therapy market in Germany?

Autologous cells are valued between $300.0 Million and $1500.0 Million. Read More

Which indications are most prevalent in the car t-cell-therapy market in Germany?

Non-Hodgkin Lymphoma shows a valuation range of $250.0 Million to $1200.0 Million. Read More

What are the primary end users of car t-cell-therapy in Germany?

Hospitals account for a valuation range of $276.42 Million to $1350.0 Million. Read More

Who are the leading companies in the car t-cell-therapy market in Germany?

Key players include Novartis, Gilead Sciences, and Bristol-Myers Squibb. Read More

What is the market potential for gene-edited cell sources in Germany's car t-cell-therapy market?

Gene-edited cells are valued between $142.85 Million and $674.8 Million. Read More

How does the market for autoimmune diseases compare to oncology in Germany's car t-cell-therapy sector?

The market for autoimmune diseases ranges from $150.0 Million to $750.0 Million, indicating a smaller segment compared to oncology. Read More

Germany Car T Cell Therapy Market

ID: MRFR/Pharma/48109-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Germany CAR T Cell Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), andBy End-user (Hospitals, Research Institutes, Cancer Treatment Centers) - Growth Outlook & Industry Forecast 2025 To 2035

Germany Car T Cell Therapy Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Security, Access Control and Robotics, BY Therapeutic Area (USD Million)
4.1.1 Oncology
4.1.2 Autoimmune Diseases
4.1.3 Infectious Diseases
4.2 Security, Access Control and Robotics, BY Cell Source (USD Million)
4.2.1 Autologous
4.2.2 Allogeneic
4.2.3 Gene-Edited
4.3 Security, Access Control and Robotics, BY Indication (USD Million)
4.3.1 Acute Lymphoblastic Leukemia
4.3.2 Non-Hodgkin Lymphoma
4.3.3 Multiple Myeloma
4.4 Security, Access Control and Robotics, BY End User (USD Million)
4.4.1 Hospitals
4.4.2 Research Institutes
4.4.3 Cancer Treatment Centers
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Novartis (CH)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Gilead Sciences (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Bristol-Myers Squibb (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Celgene (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Amgen (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Merck & Co. (US)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 AstraZeneca (GB)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Janssen Pharmaceuticals (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Bluebird Bio (US)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
6.3 GERMANY MARKET ANALYSIS BY CELL SOURCE
6.4 GERMANY MARKET ANALYSIS BY INDICATION
6.5 GERMANY MARKET ANALYSIS BY END USER
6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
6.7 RESEARCH PROCESS OF MRFR
6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AREA, 2024 (% SHARE)
6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY CELL SOURCE, 2024 (% SHARE)
6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY CELL SOURCE, 2024 TO 2035 (USD Million)
6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY INDICATION, 2024 (% SHARE)
6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY INDICATION, 2024 TO 2035 (USD Million)
6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 (% SHARE)
6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 TO 2035 (USD Million)
6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 Germany MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
7.2.2 BY CELL SOURCE, 2025-2035 (USD Million)
7.2.3 BY INDICATION, 2025-2035 (USD Million)
7.2.4 BY END USER, 2025-2035 (USD Million)
7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Therapeutic Area (USD Million, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases

Security, Access Control and Robotics By Cell Source (USD Million, 2025-2035)

Autologous
Allogeneic
Gene-Edited

Security, Access Control and Robotics By Indication (USD Million, 2025-2035)

Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma

Security, Access Control and Robotics By End User (USD Million, 2025-2035)

Hospitals
Research Institutes
Cancer Treatment Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓